Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Lewis R. Silverman(Icahn School of Medicine at Mount Sinai), Pierre Fenaux(Saint Louis University Hospital), N. Azarnia(Onconova Therapeutics (United States)), Suman Kambhampati(Veterans Health Administration), François Wilhelm(Onconova Therapeutics (United States)), Peter L. Greenberg(Stanford University), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Maria R. Baer(University of Maryland, Baltimore), Mikkael A. Sekeres(University of Miami), Lucy A. Godley(University of Chicago), Ehab Atallah(Medical College of Wisconsin), Bart L. Scott(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Uwe Platzbecker(National Center for Tumor Diseases), Robert H. Collins(Texas Oncology), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), David P. Steensma(Harvard University), Aref Al‐Kali(Mayo Clinic), Karl-Anton Kreuzer(Centrum für Integrierte Onkologie), Gail J. Roboz(Cornell University)
Cited by 172
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k